Eli Lilly and Company has started separate Phase 1 trials of antibody treatments that could potentially prevent and treat COVID-19. In the first trial, Lilly is collaborating with AbCellera Biologics Inc of Canada and in the second, with Junshi Biosciences of China. In both programmes, the companies will attempt to show that an antibody directed against the spike protein of the coronavirus can block the virus from attaching and entering cells, thus neutralising it.
